-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$25.83176.85% Upside
Phathom Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Phathom Pharmaceuticals, Inc.?
Phathom Pharmaceuticals, Inc. has been rated by research analysts at Goldman Sachs, H.C. Wainwright, Stifel Nicolaus, Needham, BMO Capital, Guggenheim in the past 90 days.